Patients with first new onset focal seizure, with or without focal to bilateral tonic clonic seizures, and generalized tonic clonic seizures and had clinical information of the first seizure confirmed by EEG or 24 hours video EEG monitoring and received perampanel as the first antiseizure medication with monotherapy Perampanel, monotherapy, Neurosurgical intensive care unit, focal-onset seizures, focal to bilateral tonic-clonic seizures, and generalized tonic-clonic seizures, drug-resistant
Conditions
Interventions
Data from all 76 patients who received PER as an add-on or monotherapy between July 2020 and
April 2024. The observation period was 6 months. The observation endpoint is the drug response and retenti
AMPA receptor antagonist,usual care
Sponsors
Phramongkutklao Hospital Foundation
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: Drug-resistant focal epilepsy patients over the age of 20 were invited to participate in the study at our Division. Drug-resistant epilepsies are defined as individuals who fail to achieve seizure free despite using two anti-seizure medicines, either polytherapy or sequential monotherapy, and adhering to a strict treatment regimen.
Exclusion criteria
Exclusion criteria: Patients who refused to fill out questionnaires for the trial were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| neurological outcome 6 month seizure frequency of 50% (50% responder rate) ,seizure outcom 6 months drug response and retention rate at 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| treatment emergent adverse events 6 months modified ranking score at 6 months,factors associated with seizure-free 6 months protective factor in seizure free group | — |
Countries
Thailand
Contacts
Public ContactPANU BOONTOTERM
Phramongkutklao College of Medicine and Hospital
Outcome results
None listed